Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting-Reference-Cited by-同舟云学术

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

Published:2016-02-02 Issue:14 Volume:7 Page:17616-17630
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Theisen Emily R.¹,Pishas Kathleen I.¹²,Saund Ranajeet S.¹,Lessnick Stephen L.¹³

Affiliation:

1. Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA

2. Cancer Therapeutics Laboratory, Centre for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia

3. Division of Pediatric Hematology/Oncology/Bone Marrow Transplant at The Ohio State University, Columbus, Ohio, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLI1 in PBMCs contributes to elevated inflammation in combat-related posttraumatic stress disorder;Frontiers in Psychiatry;2024-07-30

2. Cadherin-11 contributes to the heterogenous and dynamic Wnt-Wnt-β-catenin pathway activation in Ewing sarcoma;PLOS ONE;2024-06-14

3. Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates;Biochemistry;2024-05-14

4. Characterization of transcriptional heterogeneity and novel therapeutic targets using single cell RNA-sequencing of primary and circulating Ewing sarcoma cells;2024-01-20

5. Primary adrenal Ewing sarcoma: A systematic review of the literature;World Journal of Clinical Cases;2023-10-06